Precedent Transaction Analysis (PTA), Explained
Where Comparable Company Analysis asks “what is the market pricing similar businesses at today?”, Precedent Transaction Analysis asks “what have buyers actually paid to own them?” The difference between those two questions is worth real money.
Precedent Transaction Analysis (PTA), also called “transaction comps” or “deal comps”, derives valuation multiples from completed acquisitions and financing rounds. It is the second pillar of the market approach, sitting alongside Comparable Company Analysis (CCA). Both produce multiples; they simply draw them from different evidence, and that difference shapes the result.
What is Precedent Transaction Analysis?
PTA looks at the prices paid in real transactions involving comparable companies, M&A deals, private-equity buyouts and venture financing rounds. For each deal you compute the multiple implied by the price (EV/Sales or EV/EBITDA at the time), assemble a set of comparable transactions, and apply a representative multiple to your target. Because these are prices buyers committed real capital to, they are a powerful read on what a business is genuinely worth to an acquirer.
PTA captures the control premium. A transaction multiple reflects the price of owning and controlling a company, usually higher than the minority, freely-traded price behind CCA. That premium is information, but it means PTA and CCA answer subtly different questions and should not be averaged together blindly.
CCA vs PTA: when to use which
| Dimension | CCA (trading comps) | PTA (transaction comps) |
|---|---|---|
| Evidence | Listed peers trading now | Completed deals |
| Value type | Minority, marketable | Controlling, often premium |
| Data freshness | Live, continuous | Point-in-time, can be stale |
| Transparency | High (public financials) | Lower (deal terms often private) |
| Best when | Pricing an ongoing minority stake | Pricing an acquisition / change of control |
In practice, professional valuations triangulate: CCA frames the current market level, PTA frames what acquirers will pay, and the two together bracket a defensible range.
Why PTA is powerful
The core strength is realism. A trading multiple is an opinion; a transaction multiple is a decision. For private companies in particular, financing rounds and M&A deals are often the only observable prices available, which makes PTA indispensable where listed peers are scarce. It also reflects strategic value, the synergies and competitive motives that move acquirers, in a way that pure market comps cannot.
The data problem
PTA’s weaknesses are mostly about data quality. Deal terms are frequently confidential, so reported multiples can be incomplete or based on rumoured figures. Transactions are point-in-time events, so a comp from a different part of the cycle can mislead, a deal struck in a boom carries a multiple that no longer applies in a downturn. And every transaction has its own story: an unusually motivated buyer, a distressed seller, or a strategic premium that does not generalise.
Always date and contextualise a transaction comp. Note the cycle it occurred in and whether the deal was ordinary or special. A single headline-grabbing acquisition is the easiest way to anchor a valuation to a number that was never repeatable. See Multiples Through the Cycle for the timing adjustment.
A note on secondary transactions
Secondary transactions, where existing investors sell their shares rather than the company raising new capital, are an increasingly important source of PTA evidence, especially when primary rounds are rare. But they require care: secondary prices often carry discounts of 10-30% in normal markets and far more in stressed ones, reflecting illiquidity and the seller’s motivation. We cover how to read them in Down Rounds, Distressed & Secondary Deals.
Transaction multiples, structured.
DealMatrix blends public-market baselines with proprietary VC, PE and M&A transaction data into clean, sector-specific multiples, so your PTA isn’t hostage to one rumoured deal.
Sources & further reading
- IPEV (2025). International Private Equity and Venture Capital Valuation Guidelines.
- Damodaran, A. (2009). Valuing Young, Start-up and Growth Companies.
- DealMatrix (2026). Multiples Methodology.